Mraz Amerine & Associates’s GSK GSK Stock Holding History

Mraz Amerine & Associates’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-18,195	Closed	-$1.14M	–	134
2013 Q2	$1.14M	Buy	+18,195	New	+$1.15M	0.58%	37

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $7.03B AUM 11.68% 1-Year Est. Return

Mraz Amerine & Associates's GSK Position: Q3 2013 in Review

Mraz Amerine & Associates sold out of GSK (GSK) in Q3 2013, closing a stake of 18,195 shares — an estimated $1.14M sold.

Mraz Amerine & Associates first reported a position in GSK in Q2 2013 and held it in 1 quarter. The position peaked at $1.14M in Q2 2013. 635 funds tracked by Wall St. Rank hold GSK as of Q3 2013.

Mraz Amerine & Associates reported no remaining GSK position as of Q3 2013 after selling out during the quarter.
Mraz Amerine & Associates sold 18,195 GSK shares in Q3 2013, an estimated $1.14M.
Mraz Amerine & Associates first reported a position in GSK in Q2 2013 and held it in 1 quarter.
Mraz Amerine & Associates's GSK position peaked at $1.14M in Q2 2013.
635 funds tracked by Wall St. Rank held GSK as of Q3 2013.

Based on Mraz Amerine & Associates's 13F filing for Q3 2013, filed 18 Oct 2013.